Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
| Parent link: | Bulletin of Experimental Biology and Medicine: Scientific Journal Vol. 160, iss. 2.— 2016.— [P. 283–285] |
|---|---|
| Ente Autore: | Национальный исследовательский Томский политехнический университет Институт неразрушающего контроля Кафедра экологии и безопасности жизнедеятельности |
| Altri autori: | Ivanova S. A. Svetlana Aleksandrovna, Smirnova L. P., Shchigoreva Y. G. Yuliya Gennadjevna, Semke A. V. Arkady Valentinovich, Bokhan N. A. Nikolay Aleksandrovich |
| Riassunto: | Title screen Serum concentrations of oxidized and reduced glutathione were measured in 73 patients with schizophrenia at admission and in dynamics of therapy with traditional and atypical antipsychotic drugs. The level of reduced glutathione in patients with schizophrenia with manifest clinical symptoms was lower than in normal subjects. Atypical neuroleptics produced virtually no effects on the glutathione system, while therapy with typical antipsychotics led to further decrease in the levels of reduced glutathione, thus aggravating the imbalance of metabolic processes typical of schizophrenia. Режим доступа: по договору с организацией-держателем ресурса |
| Lingua: | inglese |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | http://dx.doi.org/10.1007/s10517-015-3151-y |
| Natura: | Elettronico Capitolo di libro |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=649823 |
Documenti analoghi
Glutamate Concentration in the Serum of Patients with Schizophrenia; Procedia Chemistry; Vol. 10 : Chemistry and Chemical Engineering in XXI century
Pubblicazione: (2014)
Pubblicazione: (2014)
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia; Heliyon; Vol. 5, iss. 7
Pubblicazione: (2019)
Pubblicazione: (2019)
A distinct serum protein pattern in patients with paranoid schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 4
Pubblicazione: (2017)
Pubblicazione: (2017)
Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics; Schizophrenia Research; Vol. 182
Pubblicazione: (2017)
Pubblicazione: (2017)
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia; The World Journal of Biological Psychiatry; Vol. 18, iss. 3
Pubblicazione: (2016)
Pubblicazione: (2016)
NMDA glutamate receptor polymorphisms modulate antipsychotic-induced hyperprolactinemia in schizophrenia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 143
Pubblicazione: (2025)
Pubblicazione: (2025)
A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia; BMC Medical Genetics; Vol. 20
Pubblicazione: (2019)
Pubblicazione: (2019)
Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome; Frontiers in Psychiatry; Vol. 10
Pubblicazione: (2019)
Pubblicazione: (2019)
Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy; Neurochemical Journal; Vol. 12, iss. 4
Pubblicazione: (2018)
Pubblicazione: (2018)
Study of OH- Radicals in Human Serum Blood of Healthy Individuals and Those with Pathological Schizophrenia; International journal of molecular sciences; Vol. 12, iss. 1
Pubblicazione: (2011)
Pubblicazione: (2011)
Voltammetric Study of the Total Activity of Antioxidants in the Blood Serum of Patients with Neurological Diseases; Chemosensors; Vol. 9, iss. 5
Pubblicazione: (2021)
Pubblicazione: (2021)
A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 105
Pubblicazione: (2021)
Pubblicazione: (2021)
Biological Optimization of Dose Distribution to Reduce the Patient Radiation Exposure during Hypofractionated Radiation Therapy; Biomedical Engineering; Vol. 55, iss. 5
di: Sukhikh E. S. Evgeniya Sergeevna
Pubblicazione: (2022)
di: Sukhikh E. S. Evgeniya Sergeevna
Pubblicazione: (2022)
Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4
Pubblicazione: (2020)
Pubblicazione: (2020)
Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 1
Pubblicazione: (2017)
Pubblicazione: (2017)
CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects; Bulletin of Experimental Biology and Medicine; Vol. 160, iss. 5
Pubblicazione: (2016)
Pubblicazione: (2016)
Perfusion and metabolic scintigraphy with 123I-BMIPP in prognosis of cardiac resynchronization therapy in patients with dilated cardiomyopathy; Annals of Nuclear Medicine; Vol. 30, iss 5
Pubblicazione: (2016)
Pubblicazione: (2016)
Voltammetric sensor for total cholesterol determination in blood serum; Theoretical and experimental chemistry
di: Derina K. V. Kseniya Vladimirovna
Pubblicazione: (2017)
di: Derina K. V. Kseniya Vladimirovna
Pubblicazione: (2017)
Patterns of electrochemical reduction of glutathione on a carbon-containing electrode modified with gold; Theoretical and experimental chemistry
di: Gashevskaya A. S.
Pubblicazione: (2017)
di: Gashevskaya A. S.
Pubblicazione: (2017)
Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients; International Journal of Obesity; Vol. 42, iss. 4
Pubblicazione: (2018)
Pubblicazione: (2018)
Physical therapy methods in the treatment and rehabilitation of cancer patients; AIP Conference Proceedings; Vol. 1760 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016
Pubblicazione: (2016)
Pubblicazione: (2016)
u-nanoparticles based sensors for voltammetric determination of glutathione; Current Analytical Chemistry; Vol. 12
Pubblicazione: (2016)
Pubblicazione: (2016)
Neurobiological mechanisms associated with antipsychotic drug-induced dystonia; Journal of Psychopharmacology; Vol. 35, iss. 1
di: Loonen A. J. M. Anton
Pubblicazione: (2021)
di: Loonen A. J. M. Anton
Pubblicazione: (2021)
Schizophrenia Methods and Protocols /
Pubblicazione: (2023)
Pubblicazione: (2023)
Voltammetric Method for Determination of Glutathione on a Gold-Carbon-Containing Electrode; Inorganic Materials; Vol. 56, iss. 11
Pubblicazione: (2020)
Pubblicazione: (2020)
Voltammetric determination of cholesterol in human blood serum; Journal of Analytical Chemistry; Vol. 72, iss. 8
Pubblicazione: (2017)
Pubblicazione: (2017)
Neuropsychology of Schizophrenia An Introduction for Psychotherapists /
di: Thoma, Patrizia
Pubblicazione: (2022)
di: Thoma, Patrizia
Pubblicazione: (2022)
Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer; Experimental Lung Research; Vol. 42, № 2
Pubblicazione: (2016)
Pubblicazione: (2016)
Electrochemical Activity of Glutathione at a Graphite Electrode Modified with Gold Nanoparticles; Oriental journal of chemistry; Vol. 31, № 2
Pubblicazione: (2015)
Pubblicazione: (2015)
Effects of Dynamic and Static Loads on the Concentration of Sodium and Potassium in Murine Skeletal Muscles; Bulletin of Experimental Biology and Medicine; Vol. 169, iss. 1
Pubblicazione: (2020)
Pubblicazione: (2020)
Study of total antioxidant activity of human serum blood in the pathology of alcoholism; Molecules; Vol. 18, iss. 2
Pubblicazione: (2013)
Pubblicazione: (2013)
Serum/Plasma Proteomics Methods and Protocols /
Pubblicazione: (2023)
Pubblicazione: (2023)
Serum/Plasma Proteomics Methods and Protocols /
Pubblicazione: (2017)
Pubblicazione: (2017)
Serum/Plasma Proteomics Methods and Protocols /
Pubblicazione: (2011)
Pubblicazione: (2011)
Obtaining and investigation of silver nanoparticles and their bioconjugates with the bovine serum albumin for the electrochemical immuneassay; Theoretical and experimental chemistry
Pubblicazione: (2017)
Pubblicazione: (2017)
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia; Frontiers in Molecular Neuroscience; Vol. 13
Pubblicazione: (2020)
Pubblicazione: (2020)
Reverse micellar partitioning of Bovine Serum Albumin with novel system; Resource-Efficient Technologies; Vol. 3, iss. 4
di: Swapnali S. Pawar
Pubblicazione: (2017)
di: Swapnali S. Pawar
Pubblicazione: (2017)
Imbalance in the glutathione system in Opisthorchis felineus infected liver promotes hepatic fibrosis; International Journal of Nanomedicine; Vol. 192
Pubblicazione: (2019)
Pubblicazione: (2019)
The Neuropsychopathology of Schizophrenia Molecules, Brain Systems, Motivation, and Cognition /
Pubblicazione: (2016)
Pubblicazione: (2016)
Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions: Chap. 6; Schizophrenia Treatment - The New Facets
di: Loonen A. J. M. Anton
Pubblicazione: (2016)
di: Loonen A. J. M. Anton
Pubblicazione: (2016)
Documenti analoghi
-
Glutamate Concentration in the Serum of Patients with Schizophrenia; Procedia Chemistry; Vol. 10 : Chemistry and Chemical Engineering in XXI century
Pubblicazione: (2014) -
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia; Heliyon; Vol. 5, iss. 7
Pubblicazione: (2019) -
A distinct serum protein pattern in patients with paranoid schizophrenia; Physiology and Pharmacology; Vol. 21, iss. 4
Pubblicazione: (2017) -
Prolactin gene polymorphism (- 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics; Schizophrenia Research; Vol. 182
Pubblicazione: (2017) -
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia; The World Journal of Biological Psychiatry; Vol. 18, iss. 3
Pubblicazione: (2016)